MapLight Therapeutics: CAO and interim CFO Jonathan Gillis sold 10,167 shares

What happened Jonathan Gillis, CAO and interim CFO, sold 10,167 shares on Oct 15, 2026. The filing reports a weighted average sale price of $8.08 and total proceeds of $82,149.

Key details

• Transaction date and price: Oct 15, 2026; weighted average price $8.08; individual sale prices ranged from $7.755 to $8.3732. Transaction code: S (sale).
• Shares owned after the transaction: not reported in the filing.
• Footnotes: F1 states the shares sold were required to be sold to cover statutory tax withholding in connection with the vesting of restricted stock units (sell-to-cover) and were not a discretionary sale by the reporting person. F2 notes the reported price is a weighted average and offers to provide a breakdown of the number of shares sold at each separate price on request.
• Filing date: Oct 16, 2026 (reporting the Oct 15, 2026 transaction). The filing does not indicate lateness.

Why it may matter

• The filing states this was a sell-to-cover to satisfy tax withholding on RSU vesting, not a discretionary open-market sale.
• The filing does not show why the insider traded or why the company acted.